We are pleased to announce that an interview with Eiji Tahara, Representative Director and CEO of Periotherapia Co., Ltd., has been published in the May 1, 2026 issue of Iyaku Keizai (Medical & Pharmaceutical Economy), a leading specialized journal dedicated to the pharmaceutical and healthcare industry in Japan.

The interview, titled “A New Strategy Challenging with Periostin-Targeting Antibodies,” features Mr. Tahara discussing the company’s development strategy for periostin-targeting antibody therapeutics, as well as the future vision of Periotherapia Co., Ltd.We invite you to read the issue for further details.

Please note that this article is available exclusively to paid subscribers of Iyaku Keizai in Japanese only.https://iyakukeizai.com/iyakukeizaiweb/detail/180340